Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
macular degeneration
Biotech
Merck has clear vision to eye disease assets with $3B EyeBio buy
Merck & Co. is focusing in on eye diseases with the $3 billion acquisition of ophthalmology-focused Eyebiotech.
Annalee Armstrong
May 29, 2024 8:32am
Boehringer taps RetinAI for AI boost to eye disease R&D
Apr 21, 2023 9:35am
AbbVie bets $370M on pivotal eye disease gene therapy
Sep 13, 2021 8:45am
Half of Adverum eye disease pipeline 'snaps out of existence'
Jul 23, 2021 5:34am
Treating blindness with a stem cell transplant
Jan 14, 2021 11:00am
Restoring eyesight with genetically engineered stem cells
Dec 1, 2020 11:00am
